Effect of time-dependent covariate^{*} | Treatment group adjusted for specific time-dependent covariate^{*} | |||
---|---|---|---|---|

Time-dependent covariate | HR (95% CI) | P value | HR (95% CI) | P value |

None | — | — | 0.70 (0.52, 0.93) | 0.0151 |

Sustained microalbuminuria (yes vs. no)^{‡} | 2.28 (1.67, 3.11) | <0.0001 | 0.78 (0.58, 1.05) | 0.1038 |

Macroalbuminuria (yes vs. no)^{§} | 2.22 (1.46, 3.38) | 0.0002 | 0.75 (0.56, 1.01) | 0.0594 |

Kidney failure (yes vs. no)^{¶} | 4.84 (1.93, 12.11) | 0.0008 | 0.71 (0.53, 0.95) | 0.0199 |

Mean HbA_{1c} during DCCT/EDIC^{#} | ||||

Per 10% increase | 1.35 (1.21, 1.51) | <0.0001 | 1.00 (0.72, 1.39) | 0.9843 |

Per 10% decrease | 0.72 (0.63, 0.81) |

↵*Each of the above five models was also adjusted for the following DCCT baseline characteristics: HbA

_{1c}value, age, cholesterol level, and smoking status.↵‡Sustained microalbuminuria was defined by a history of microalbuminuria (AER ≥30 mg/24 h) on at least two consecutive visits, or ESRD (dialysis or transplant).

↵§Macroalbuminuria was defined by a history of albuminuria (AER ≥300 mg/24 h) or ESRD.

↵¶Kidney failure was defined by a history of eGFR <15 mL/min/1.73 m

^{2}or ESRD.↵#The weighted mean HbA

_{1c}up to the time of each CVD event was calculated as the weighted mean of the quarterly values during DCCT plus the annual values during EDIC, weighted respectively by ¼ and 1 to reflect the interval between values during the DCCT and EDIC. The log mean HbA_{1c}value was used so that the HR per*c*-fold change in risk is*c3.17155*, where 3.17155 is the estimated regression coefficient; a*c*of 1.1 corresponds to a 10% increase in the mean glycosylated hemoglobin value, and a*c*of 0.9 to a 10% decrease.